Skip to content
Medical Health Aged Care

Arthritis Australia welcomes cheaper arthritis medicines

Issued by Cube on behalf of Arthritis Australia 2 mins read

MEDIA RELEASE: 1st March 2024


More medicines now eligible for 60 day dispensing from March 1 2024


[Sydney, Australia] Arthritis Australia has welcomed access to cheaper medicines commonly used to treat arthritis, with the rollout of a new tranche of medicines eligible for 60 day dispensing from March 1 2024.

Doctors will be able to write a 12-month script for medicines commonly used for arthritis conditions, including prednisolone, methotrexate DBL, Leflunomide and Ciclosporin, allowing a two-month supply to be dispensed when patients visit their pharmacy.

Arthritis Australia CEO Jonathan Smithers said “Many people living with arthritis who are struggling with the costs of their healthcare have been waiting for this day. About three quarters of people with arthritis have at least one other chronic condition, so many will also benefit from cheaper scripts for other conditions including mental health and diabetes.

“People with arthritis are often on lower incomes or unable to work due to their condition, and are financially stressed with the cost of living pressures and the combined cost of all their treatments and appointments,” he adds.

“We are really pleased the Government has prioritised the needs of consumers in rolling out these measures, which follow the recent reduction to PBS copayments.”

Annique Daran, 44, from Sydney, who lives with ankylosing spondylitis, has been taking prednisolone tablets for 7 years. “As a working mum with a toddler, managing a chronic condition can be tough and expensive. Saving money on medicines will make a difference for my family, and it will also really help being able to make less trips to the doctor or pharmacy for routine scripts.”

Currently, almost 4 million Australians of all ages are living with arthritis. Arthritis Australia and its affiliates are witnessing an increase in those facing financial distress, withdrawing from programs and delaying or not receiving the care they need. People are making difficult decisions not to fill their prescriptions or pursue specialist referrals due to cost.

Available for interview: Jonathan Smithers, CEO, Arthritis Australia

About us:

About Arthritis Australia

Arthritis Australia is the peak national body for arthritis, advocating on behalf of over 4 million Australians living with arthritis, and working with many other arthritis organisations to deliver information and support to people living with more than 100 types of arthritis and musculoskeletal conditions. We are a leading non-government funder of arthritis research in Australia and advocate for policies, programs and funding initiatives that will improve the health and wellbeing of people living with arthritis. For more information visit:

Contact details:

For more information, please contact: Anne-Marie Sparrow on 0417 421 560

More from this category

  • Medical Health Aged Care
  • 15/06/2024
  • 04:30
Dementia Australia

Join us TODAY for Hunter Walk & Jog

What: Dementia Australia’sHunterMemory Walk & Jog. When: Saturday 15 June from 7.30am. Who: More than 750 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Where: Speers Point Park, Speers Point For more information visit: Walk or jog with us. We are in this together. Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support…

  • Contains:
  • Medical Health Aged Care
  • 14/06/2024
  • 22:07
Takeda Pharmaceutical Company Limited

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

− Takeda to Receive Exclusive Option to License Global Rights to Olverembatinib in All Territories Outside of Mainland China, Hong Kong, Macau, Taiwan and…

  • Contains:
  • Disability, Medical Health Aged Care
  • 14/06/2024
  • 09:44


A new survey commissioned by hearing care expertsAudika Hearing Clinic reveals surveyed Australians prioritise their sight over hearing, despite over three quarters (77%) knowing someone who is hard of hearing. Most (86%) respondents ranked sight as their most important sense, with hearing coming in second (69%)[1]. Unsurprisingly, this is reflected in which sense they care for more, with almost three quarters (73%) of respondents admitting that between hearing and sight, their hearing was the most neglected[1]. Reasons for neglect: Lack of understanding and stigma Both stigma and a lack of understanding can impact the way Australians prioritise their senses. Interestingly,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.